Curis to Participate at the Upcoming 2024 Cantor Fitzgerald Global Healthcare Conference

Rhea-AI Summary

Curis Inc (NASDAQ: CRIS), a biotechnology company developing emavusertib (CA-4948), an oral IRAK4 inhibitor, announced its participation in the 2024 Cantor Fitzgerald Global Healthcare Conference. James Dentzer, President and CEO of Curis, will engage in a fireside chat on September 17, 2024, at 4:15 PM ET.

The event will be accessible via webcast through the Cantor link and on the Curis website in the Investors section. This participation underscores Curis's commitment to engaging with the investment community and showcasing its progress in developing innovative therapies for cancer treatment.

News Market Reaction – CRIS

+5.11%

1 alert

+5.11% News Effect

On the day this news was published, CRIS gained 5.11%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

LEXINGTON, Mass., Sept. 17, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that James Dentzer, President and Chief Executive Officer of Curis, will participate in a fireside chat at the 2024 Cantor Fitzgerald Global Healthcare Conference later today at 4:15 PM ET. Details for the webcast can be found using the Cantor webcast link.

The webcast will be also available on the Curis website at www.curis.com in the 'Investors' section.

About Curis, Inc.

Curis is a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor. Emavusertib is currently undergoing testing in the Phase 1/2 TakeAim Lymphoma study (CA-4948-101) in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase 1/2 TakeAim Leukemia study (CA-4948-102) in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS) with either a FLT3 mutation or a splicing factor mutation (U2AF1 or SF3B2), and as a frontline combination therapy with azacitidine and venetoclax in patents with AML (CA-4948-104). Emavusertib has received Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of AML and MDS and from the European Commission for the treatment of PCNSL. Curis, through its 2015 collaboration with Aurigene, has the exclusive license to emavusertib (CA-4948). Curis licensed its rights to Erivedge® to Genentech, a member of the Roche Group, under which they are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis's website at www.curis.com. 

View original content to download multimedia:https://www.prnewswire.com/news-releases/curis-to-participate-at-the-upcoming-2024-cantor-fitzgerald-global-healthcare-conference-302249626.html

SOURCE Curis, Inc.

FAQ

When is Curis (CRIS) presenting at the 2024 Cantor Fitzgerald Global Healthcare Conference?

Curis (CRIS) is presenting at the 2024 Cantor Fitzgerald Global Healthcare Conference on September 17, 2024, at 4:15 PM ET.

Who will represent Curis (CRIS) at the 2024 Cantor Fitzgerald Global Healthcare Conference?

James Dentzer, President and Chief Executive Officer of Curis, will represent the company in a fireside chat at the conference.

What is the main drug candidate Curis (CRIS) is developing?

Curis is focusing on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor.

How can investors access Curis's (CRIS) presentation at the Cantor Fitzgerald conference?

Investors can access the presentation via webcast through the Cantor link or on the Curis website at www.curis.com in the 'Investors' section.